Adolescent patients' eczema improved in Leo Pharma's late-stage testing
Two phase III trials give the Danish dermatology company hope to see tralokinumab’s approved indication expanded to include the younger segment of teens.
by ulrich quistgaard, translated by daniel pedersen
Leo Pharma has presented results from two concurrent phase III trials of tralokinumab, which is already approved in the atopic dermatitis indication.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
